Unidentified CYP2D6 genotype does not affect pharmacological treatment for patients with first episode psychosis.

ABSTRACT:

Background

Research on the pharmacogenetic influence of hepatic CYP450 enzyme 2D6 (CYP2D6) on metabolism of drugs for psychosis and associated outcome has been inconclusive. Some results suggest increased risk of adverse reactions in poor and intermediate metabolizers, while others find no relationship. However, retrospective designs may fail to account for the long-term pharmacological treatment of patients. Previous studies found that clinicians adapted risperidone dose successfully without knowledge of patient CYP2D6 phenotype.

Aim

Here, we aimed to replicate the results of those studies in a Dutch cohort of patients with psychosis (N = 418) on pharmacological treatment.

Method

We compared chlorpromazine-equivalent dose between CYP2D6

SUBMITTER: De Brabander EY 

PROVIDER: S-EPMC11528939 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature